News

Yahoo Finance6mon
TORL BioTherapeutics Announces Appointment of Aran Maree, M.D., as Chief Medical Officer and Initiates TORL-1-23 Registration-Enabling Phase 2 Study in Platinum-Resistant ...
Alles, Chairman and Chief Executive Officer of TORL Biotherapeutics. "Aran Maree is among the most accomplished and experienced physician-leaders in the biopharmaceutical industry, and TORL will ...
Yahoo Finance8mon
TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress
TORL-1-23 Demonstrates Clinically Meaningful, Durable and Confirmed Responses with a Generally Manageable Safety Profile in Patients with Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian ...
pharmaphorum6d
TORL rakes in $158m for ADCs, and other bio financings
Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics. Antibody-drug conjugate specialist TORL ...
The Victoria Advocate6mon
TORL BioTherapeutics Announces Appointment of Aran Maree, M.D., as Chief Medical Officer and Initiates TORL-1-23 Registration-Enabling Phase 2 Study in Platinum-Resistant ...
You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...
WREG8mon
TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress
TORL BioTherapeutics, LLC (TORL Bio) is a clinical-stage biopharmaceutical company developing new antibodies, both monoclonal (mAbs) and drug conjugates (ADCs), with the goal of transforming the ...